Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.69
ALXA's Cash to Debt is ranked higher than
59% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. ALXA: 0.69 )
ALXA' s 10-Year Cash to Debt Range
Min: 0.69   Max: No Debt
Current: 0.69

Equity to Asset -0.48
ALXA's Equity to Asset is ranked lower than
59% of the 728 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. ALXA: -0.48 )
ALXA' s 10-Year Equity to Asset Range
Min: -0.6   Max: 0.84
Current: -0.48

-0.6
0.84
Interest Coverage 1.18
ALXA's Interest Coverage is ranked lower than
56% of the 454 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.71 vs. ALXA: 1.18 )
ALXA' s 10-Year Interest Coverage Range
Min: 1.18   Max: 9999.99
Current: 1.18

1.18
9999.99
F-Score: 2
Z-Score: -7.77
M-Score: 50.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 3.70
ALXA's Operating margin (%) is ranked higher than
64% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. ALXA: 3.70 )
ALXA' s 10-Year Operating margin (%) Range
Min: -16197.53   Max: 10.85
Current: 3.7

-16197.53
10.85
Net-margin (%) -82.81
ALXA's Net-margin (%) is ranked lower than
52% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. ALXA: -82.81 )
ALXA' s 10-Year Net-margin (%) Range
Min: -12026.75   Max: -3.45
Current: -82.81

-12026.75
-3.45
ROA (%) -84.16
ALXA's ROA (%) is ranked lower than
56% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. ALXA: -84.16 )
ALXA' s 10-Year ROA (%) Range
Min: -224.46   Max: -2.16
Current: -84.16

-224.46
-2.16
ROC (Joel Greenblatt) (%) 11.81
ALXA's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. ALXA: 11.81 )
ALXA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -518.48   Max: 19.1
Current: 11.81

-518.48
19.1
Revenue Growth (%) -28.20
ALXA's Revenue Growth (%) is ranked lower than
52% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. ALXA: -28.20 )
ALXA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 85.6
Current: -28.2

0
85.6
EPS Growth (%) 106.60
ALXA's EPS Growth (%) is ranked higher than
98% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. ALXA: 106.60 )
ALXA' s 10-Year EPS Growth (%) Range
Min: -74.2   Max: 106.6
Current: 106.6

-74.2
106.6
» ALXA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ALXA Guru Trades in

Q2 2012

ALXA Guru Trades in Q2 2012

Jim Simons 27,741 sh (+24.43%)
» More
Q3 2012

ALXA Guru Trades in Q3 2012

Jim Simons 158,201 sh (+470.28%)
» More
Q4 2012

ALXA Guru Trades in Q4 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ALXA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 8.12
ALXA's P/S is ranked lower than
56% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. ALXA: 8.12 )
ALXA' s 10-Year P/S Range
Min: 1.25   Max: 2725
Current: 8.12

1.25
2725
EV-to-EBIT -1.65
ALXA's EV-to-EBIT is ranked higher than
58% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. ALXA: -1.65 )
ALXA' s 10-Year EV-to-EBIT Range
Min: 2.7   Max: 288.8
Current: -1.65

2.7
288.8
Current Ratio 5.31
ALXA's Current Ratio is ranked higher than
87% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. ALXA: 5.31 )
ALXA' s 10-Year Current Ratio Range
Min: 0.63   Max: 10.75
Current: 5.31

0.63
10.75
Quick Ratio 4.90
ALXA's Quick Ratio is ranked higher than
88% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. ALXA: 4.90 )
ALXA' s 10-Year Quick Ratio Range
Min: 0.6   Max: 10.75
Current: 4.9

0.6
10.75

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.85
ALXA's Price/Median PS Value is ranked higher than
88% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. ALXA: 0.85 )
ALXA' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 260
Current: 0.85

0.15
260
Earnings Yield (Greenblatt) 3.90
ALXA's Earnings Yield (Greenblatt) is ranked higher than
68% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. ALXA: 3.90 )
ALXA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 37.7
Current: 3.9

0.3
37.7
Forward Rate of Return (Yacktman) -124.79
ALXA's Forward Rate of Return (Yacktman) is ranked lower than
55% of the 633 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. ALXA: -124.79 )
ALXA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -202.4   Max: -83.9
Current: -124.79

-202.4
-83.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:N3VN.Germany
Alexza Pharmaceuticals, Inc. is incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc. In June 2001, it changed the name to Alexza Corporation and in December 2001 it became Alexza Molecular Delivery Corporation. In July 2005, it changed the name to Alexza Pharmaceuticals, Inc. It is a pharmaceutical company focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. ADASUVE, or Staccato loxapine, and its product candidates are based on its proprietary technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of the Company's product candidates are subject to extensive regulation by governmental authorities in the United States and other countries. The pharmaceutical and biotechnology industries are intensely competitive. Many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations are actively engaged in research and development of products targeting the same markets as ADASUVE and its other product candidates.
» More Articles for ALXA

Headlines

Articles On GuruFocus.com
Wrong Marketing Lesson by Big Pharma May 03 2014 
Weekly CEO Buys Highlight: RCL, PSXP, ALXA, PAY, HAFC Aug 05 2013 
Royal Caribbean and Four Others Report $100 Thousand CEO Buys Jul 31 2013 
President and CEO of Alexza Pharmaceuticals Inc. Thomas Braxton King Bought 40,000 Shares Jul 29 2013 
Weekly CEO Buys Highlight: NYLD, ALXA, DOC, NTWK, SNV Jul 29 2013 
Alexza Pharmaceuticals Inc. (ALXA) SVP, CFO & Sec August J Moretti sells 10,000 Shares May 07 2010 
cooldecency99 note on ALXA May 01 2010 
Alexza Pharmaceuticals Inc. (ALXA) SVP, CFO & Sec August J Moretti sells 14,000 Shares Dec 21 2009 
Alexza Pharmaceuticals Inc. (ALXA) Pres & CEO Thomas Braxton King sells 45,000 Shares Dec 21 2009 
Weekly CEO Buy Highlight: Winmark Corp, Alexza Pharmaceuticals Inc, Ladenburg Thalmann Financial Ser Oct 11 2009 

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK